Cancer is most treatable in its early stages, so finding innovative and non-invasive methods to diagnose cancer early on is crucial for fighting the disease. Liquid biopsies, which require just a ...

Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary ...

SAINT LOUIS--(BUSINESS WIRE)--Cofactor Genomics, Inc., a clinical-stage company bridging the precision medicine gap by decoding RNA, announced the publication of their analytical validation study of ...

When a tumor starts to grow in the body, small bits of its genetic material may break away and float off into the bloodstream. This so-called cell free DNA can be used to identify cancer at very early ...

VANCOUVER, British Columbia -- The novel multitarget stool RNA test (ColoSense) showed high sensitivity for detecting colorectal neoplasia among adults ages 45 and older, according to the phase III ...

Researchers at The Institute of Cancer Research have found a dual genetic test is more accurate than the traditional approach in identifying multiple myeloma patients who may be at an elevated risk of ...

ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics, Inc., a clinical-stage company bridging the precision medicine gap by decoding RNA, announced today the validation and launch of OncoPrism ®-NSCLC, an ...

The novel Cleavage High-throughput Assay (CHiTA) developed at Penn State provides a scarless method to characterize thousands of diverse small self-cleaving RNA enzymes, called twister ribozymes, in a ...

Dr. Kayvan Zainabadi (center) is working with colleagues in Pune, India, to test the RNA-based TB diagnostic he is developing. From left: Dr. Mandar Paradkar (co-PI, pediatrician), Vidyulata Kamble, ...

Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease Ambry Genetics first implemented RNA testing in 2016 as part of a research and ...